Merck-AGITG Clinical Research Fellowship in GI Cancer

The Merck-AGITG Clinical Research Fellowship in GI Cancer is a prestigious two-year Fellowship (2021-2022) at the Royal Marsden Hospital, London, valued at  AUD$150,000.  The Fellowship provides early career researchers with an opportunity to work in the busiest GI clinic in the UK and to assist in the development of collaborative links between the AGITG and UK research groups.

A major objective of the activity is to foster career development by encouraging the beneficial experience of a different research environment.

Prof Tim Price, Chair of the AGITG, says, “We are proud to be able to continue this partnership with Merck into the second year of the Merck-AGITG Clinical Research Fellowship. This is a rare opportunity for the Fellow to train with experts in one of the UK’s most influential and busiest GI clinics, strengthening the AGITG’s links with UK researchers. Fostering international collaboration in this way is key to changing outcomes for GI cancer patients.”

Merck Healthcare Managing Director & General Manager for Australia/New Zealand, Leah Goodman, says,  “Merck is delighted to continue the company’s long standing support for research and education in the important therapy area of gastrointestinal cancer. This Fellowship aims to further the successful candidate’s study in London and bring those learnings back to clinical practice in Australia or New Zealand. It also provides an avenue for ongoing tri-national collaboration.

Merck has been involved in providing oncology medicines in Australia for many  years and we greatly value the work being undertaken by the Australasian Gastro-Intestinal Trials Group to build knowledge and ensure Australia and New Zealand stay at the forefront of treating patients with gastrointestinal diseases.”

Read the July 2019 update from recipient of the current two year Fellowship, Dr David Lau.

Applications for the 2021-22 Fellowship have now closed. The recipient will be announced at the 2020 Annual Scientific Meeting.